

=> d his

(FILE 'HOME' ENTERED AT 15:33:14 ON 19 MAR 2003)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 15:33:58 ON 19 MAR 2003

SEA CD20(10W)B CELL

47 FILE ADISCTI
4 FILE ADISINSIGHT
8 FILE ADISNEWS
2 FILE BIOBUSINESS
7 FILE BIOCOMMERCE
324 FILE BIOSIS
6 FILE BIOTECHABS
6 FILE BIOTECHDS
105 FILE BIOTECHNO
4 FILE CABA
215 FILE CANCERLIT
229 FILE CAPLUS
5 FILE CEABA-VTB
26 FILE CIN
13 FILE CONFSCI
68 FILE DDFU
9287 FILE DGENE
11 FILE DRUGNL
89 FILE DRUGU
3 FILE DRUGUPDATES
7 FILE EMBAL
238 FILE EMBASE
126 FILE ESBIOWASE
12 FILE FEDRIP
23 FILE GENBANK
16 FILE IFIPAT
34 FILE JICST-EPLUS
52 FILE LIFESCI
262 FILE MEDLINE
1 FILE NIOSHTIC
16 FILE PASCAL
4 FILE PHAR
16 FILE PHARMAML
15 FILE PHIN
98 FILE PROMT
250 FILE SCISEARCH
164 FILE TOXCENTER
162 FILE USPATFULL
16 FILE WPIDS
16 FILE WPINDEX

L1 QUE CD20(10W) B CELL

FILE 'DGENE, BIOSIS, MEDLINE, SCISEARCH, EMBASE, CAPLUS, CANCERLIT, TOXCENTER, USPATFULL, ESBIOWASE, BIOTECHNO, PROMT, DRUGU, LIFESCI, ADISCTI, JICST-EPLUS, CIN, GENBANK, IFIPAT, PASCAL, PHARMAML, WPIDS, PHIN, CONFSCI, FEDRIP, DRUGNL, ADISNEWS, BIOCOMMERCE, ...' ENTERED AT 15:35:41 ON 19 MAR 2003

L2 11897 S CD20(10W)B CELL

L3 39 S VACCIN?(10W)CD20

L4 18 DUP REM L3 (21 DUPLICATES REMOVED)
 L5 42 S CD20(25W) (EXTRACELL?) AND DOMAIN
 L6 30 DUP REM L5 (12 DUPLICATES REMOVED)
 L7 5691 S CD20(10W)ANTIBOD?
 L8 17 S L7 AND CD10(10W) (ANTIGEN OR IMMUNOGEN?)
 L9 16 DUP REM L8 (1 DUPLICATE REMOVED)
 L10 372 S B1(20W)CD20 AND (B CELL)
 L11 148 DUP REM L10 (224 DUPLICATES REMOVED)
 L12 166 S L10 AND B1(25W)ANTIBOD?
 L13 75 DUP REM L12 (91 DUPLICATES REMOVED)
 L14 425 S B1(25W)VACCINE
 L15 250 DUP REM L14 (175 DUPLICATES REMOVED)
 L16 19 S L14 AND (CANCER OR TUMOR OR TUMOUR)
 L17 15 DUP REM L16 (4 DUPLICATES REMOVED)

=>

L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2003 ACS
AN 1997:8270 CAPLUS
DN 126:103042
TI Lysis of syngeneic tumor B cells by autoreactive cytotoxic T lymphocytes
specific for a CD19 antigen-derived synthetic peptide
AU Hooijberg, Erik; Visseren, Marjan J. W.; Van Den Berk, Paul C. M.;
Jellema, Anke P.; Romeijn, Petra; Sein, Johan J.; Van Der Voort, Ellen I.
H.; Hekman, Annemarie; Ossendorp, Ferry; Melief, Cornelis J. M.
CS Department of Immunology, The Netherlands Cancer Institute/Antoni van
Leeuwenhoek Huis, Amsterdam, Neth.
SO Journal of Immunotherapy with Emphasis on Tumor Immunology (1996), 19(5),
346-356
CODEN: JIEIEZ; ISSN: 1067-5582
PB Lippincott-Raven
DT Journal
LA English
AB Cytotoxic T lymphocytes (CTL) play an important role in the destruction of
immunogenic tumors. A novel category of target antigens for CTL concerns
normal differentiation antigens as most clearly demonstrated in human
melanoma. In the case of B-cell cancers, differentiation antigens
normally expressed on B cells may be useful targets. In this report, we
have focused on the murine B-cell differentiation antigens CD19 and CD20.
We have identified 18 peptide sequences on the basis of major
histocompatibility complex (MHC) class-I binding-motifs as candidates for
the induction of autoreactive CTL. Six of the peptides were capable of
binding efficiently to either Kb or Db and were subsequently used for in
vivo induction of CTL. Vaccination with each of three peptides led to
peptide-specific CTL. Two peptides were derived from the mCD20 antigen
and one from the mCD19 antigen. CTL specific for the mCD19-derived
peptide were also capable of killing a syngeneic B-cell tumor line.
Recognition of the peptide as well as the tumor cells was shown to be Kb
restricted. This is the first report to show that autoreactive CTL
recognizing peptides derived from B-cell-specific differentiation antigens
can be generated by vaccination with a synthetic peptide.
IT Lymphoma
(B-cell; **vaccination** with CD19 or **CD20** peptides
induces cytotoxic T-lymphocytes that lyse syngeneic B-cell tumors in
mice)
IT 185856-50-2 185856-51-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(**vaccination** with CD19 or **CD20** peptides induces
cytotoxic T-lymphocytes that lyse syngeneic B-cell tumors in mice)

*Also wanted
on the
peptide
search*